Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.44 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.44 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 12/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 12/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704488 | 0.88 | ALDH1A1 (0.46) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4703977 | 0.86 | CYP1A2 (0.46) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4702154 | 0.86 | CYP1A1 (0.46) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4699100 | 0.86 | BCHE (0.42) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4701421 | 0.84 | CYP1A2 (0.54) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4699107 | 0.79 | CYP1A2 (0.46) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL5943555 | 0.78 | ALDH1A1 (0.50) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL14425117 | 0.76 | CYP1A1 (0.49) | BCHEACHECYP1A1CYP1B1CYP1A2 | |
| SCHEMBL4699059 | 0.76 | MAPT (0.41) | CYP1A2KDM4EPDE5AALDH1A1LMNA | |
| SCHEMBL14345922 | 0.75 | BCHE (0.62) | BCHEACHECYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | claimed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | claimed |
| EP-1390367-B1 | DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE | MACEF (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | GDI2, GDI1, CYP2A7 | HTR1A 226/4885ADRB2 58/4885HTR2A 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.